TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from SinoMab Bioscience Ltd. ( (HK:3681) ) is now available.
SinoMab BioScience Limited announced significant advancements in its clinical trial programs during the first half of 2025. The company’s flagship product, SM03 (Suciraslimab), showed promising preclinical results for systemic lupus erythematosus, leading to a strategic shift away from rheumatoid arthritis treatment. Additionally, SM17 demonstrated positive Phase 1b results for atopic dermatitis, highlighting its potential as a leading treatment in the field. The company is also progressing with its anti-CGC antibody for alopecia areata, with an IND application expected by 2026.
The most recent analyst rating on (HK:3681) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a Hong Kong-based biopharmaceutical company specializing in the development of monoclonal antibody-based therapeutics. The company focuses on innovative treatments for autoimmune and allergic diseases, aiming to provide first-in-class and best-in-class solutions.
Average Trading Volume: 22,579,208
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.12B
For detailed information about 3681 stock, go to TipRanks’ Stock Analysis page.